LDL-C, Cardiovascular Risk, and Nonstatin Therapy: Identifying Patients and Improving Outcomes

Registration for this program is now closed.

Despite the use of guideline-directed statin therapy, residual risk remains in individuals who have experienced a cardiovascular event. Moreover, recurrent cardiovascular events often occur within the first year after the initial event. Therefore, timely reduction of LDL-C with nonstatin therapies in patients at heightened risk is prudent for preventing major adverse cardiovascular outcomes. In this program, Chair Dr. Robert Giugliano will provide updates on LDL-C-lowering nonstatin therapy from the European Society of Cardiology meeting, as well as from recent publications. Then, faculty members Dr. Pamela Morris, Dr. Peter Toth, and Dr. Robert Eckel will identify, in an interactive case-presentation format, high risk patients for potential introduction of ezetimibe and PCSK9 inhibitors.

Educational Objectives: 

1. Recognize the importance of LDL-C lowering for atherosclerotic cardiovascular disease (ASCVD) risk reduction
2. Interpret evidence from clinical trials with PCSK9 inhibitors and ezetimibe
3. Identify patients for use of nonstatin, LDL-C-lowering therapy

Accreditation & Credit Designation:
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this live webinar for a maximum of 1.75 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits^TM through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits ^TM from organizations accredited by the ACCME.

Target Audience:  This educational activity is intended for cardiovascular clinicians.